stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

A randomized phase II, double-blind, multicenter study evaluating the efficacy and safety of autogene cevumeran plus nivolumab versus nivolumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma

Stato
Autorizzato - In attesa di apertura
Codice studio
BO45230
Codice EudraCT
2023-509023-40-00
Sponsor/Promotore
F. Hoffmann-La Roche Ltd
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Enfortumab Vedotin per il trattamento di pazienti con carcinoma uroteliale localmente avanzato o metastatico precedentemente trattato con chemioterapia e immunoterapia: uno studio italiano, multicentrico e non-interventistico. Studio EVIDENCE

Stato
Aperto - reclutamento in corso
Codice studio
7465-MA-3500 (EVIDENCE)
Codice EudraCT
NP
Sponsor/Promotore
Astellas Pharma Europe Ltd
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Efficacia e sicurezza di apalutamide in pazienti affetti da carcinoma prostatico avanzato ormono-sensibile: studio osservazionale prospettico multicentrico

Stato
Aperto - reclutamento in corso
Codice studio
INTENT (prostata)
Codice EudraCT
NP
Sponsor/Promotore
Azienda Ospedaliera Spedali Civili di Brescia
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio osservazionale prospettico internazionale di cabozantinib compresse in combinazione con nivolumab come trattamento di prima linea del carcinoma a cellule renali in stadio avanzato negli adulti

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
CLIN-60000-452
Codice EudraCT
NP
Sponsor/Promotore
Ipsen Pharma
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio di fase I/IIa, a bracci multipli, in aperto per valutare la sicurezza, la tollerabilità, la farmacocinetica, la farmacodinamica e l’efficacia preliminare di AZD5305 in combinazione con agenti ormonali di nuova generazione in pazienti con carcinoma prostatico metastatico (PETRANHA)

Stato
Aperto - reclutamento in corso
Codice studio
D9720C00003 (PETRANHA)
Codice EudraCT
2021-006289-19
Sponsor/Promotore
AstraZeneca AB
Tipologia
Sperimentale
Fase
I / II
Unità Operativa
Principal Investigator

Studio di fase II, randomizzato, multicentrico, in aperto e controllato su RO7247669 da solo o in associazione a tiragolumab rispetto ad atezolizumab in pazienti con tumore uroteliale della vescica localmente avanzato o metastatico non pretrattato non idonei a chemioterapia a base di platino

Stato
Aperto - reclutamento in corso
Codice studio
BO44157
Codice EudraCT
2022-002265-15
Sponsor/Promotore
F. Hoffmann-La Roche Ltd
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top